Clinical trial · Interventional
Blood and Marrow Transplant Clinical Research Network
NCT00023530CI-TRIAL-00020977completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this network is to accelerate research in hematopoietic stem cell transplantation by comparing novel therapies to existing ones.
Conditions
Conditions (7)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Blood Disease | — | UNRESOLVED | — |
| Bone Marrow Transplantation | — | UNRESOLVED | — |
| Graft vs Host Disease | — | UNRESOLVED | — |
| Hematopoietic Stem Cell Transplantation | — | UNRESOLVED | — |
| Leukemia | Leukemia | ONTOLOGY_EXACT | 0.90 |
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
| Myelodysplastic Syndromes | Myelodysplastic Syndrome | ALIAS | 0.90 |
Interventions
Interventions (5)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| bone marrow transplant | Procedure | — | UNRESOLVED |
| dexamethasone | Drug | Dexamethasone | ALIAS |
| fluconazole | Drug | — | UNRESOLVED |
| thalidomide | Drug | Thalidomide | ALIAS |
| voriconazole | Drug | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 2 Years
Show eligibility criteria text
Criteria for entry into a study varies by protocol
References
Publications (1)
- BACKGROUNDWingard JR. Design issues in a prospective randomized double-blinded trial of prophylaxis with fluconazole versus voriconazole after allogeneic hematopoietic cell transplantation. Clin Infect Dis. 2004 Oct 15;39 Suppl 4:S176-80. doi: 10.1086/421953. PMID 15546114